

**WHAT IS CLAIMED IS:**

1. A method of determining an individual's predisposition to epilepsy and/or development of epilepsy, as well as  
5 predicting this individual's response to medication, said method comprising the step of determining the genotype of at least one gene selected from SCN1A, SCN2A and SCN3A of the individual, or of a DNA variant, equivalent, or mutation which shows a linkage disequilibrium therewith, thereby determining an individual's predisposition to epilepsy  
10 and/or development of epilepsy.
2. The method of claim 1, wherein the step of determining the SCN1A, SCN2A or SCN3A genotype comprises restriction endonuclease digestion.
3. The method of claim 1, wherein the step of  
15 determining the SCN1A, SCN2A or SCN3A genotype comprises hybridizing with allele specific oligonucleotides.
4. The method of claim 1, which further comprises a step, prior to determining the SCN1A, SCN2A or SCN3A genotype, of amplifying a segment of the the SCN1A, SCN2A or SCN3A using  
20 polymerase chain reaction.
5. The method of claim 1, wherein the step of determining the SCN1A, SCN2A or SCN3A genotype comprises a sequencing of SCN1A, SCN2A or SCN3A , or parts thereof.
6. The method of claim 1, wherein the SCN1A,  
25 SCN2A or SCN3A genotype is determined using a polymorphic variant

site in linkage disequilibrium with at least one allelic variant or mutant identified in accordance with the present invention.

7. An assay for screening a test agent and selecting an agent which modulates inactivation of a sodium channel involved in epilepsy comprising:

- a) a recombinant SCN1A, SCN2A or SCN3A gene which encodes an alpha subunit of said sodium channel or functional fragment thereof; and
- b) assaying a function of said sodium channel;
- 10 wherein an agent can be selected when an observable difference is observed between the inactivation of said sodium channel in the presence of said test agent, as compared to in an absence thereof, and wherein a malfunction of said sodium channel is associated with epilepsy.

8. An assay for screening a test agent and selecting an agent which modulates the activity of a sodium channel involved in epilepsy comprising:

- a) a recombinant SCN1A, SCN2A or SCN3A gene which encodes an alpha subunit of said sodium channel or functional fragment thereof; and
- 20 b) assaying the activity of said sodium channel;
- wherein an agent can be selected when an observable difference is observed between the activity of said sodium channel in the presence of said test agent, as compared to in an absence thereof, and wherein a malfunction of said sodium channel is associated with epilepsy.

- 25 9. A method of using specific alleles of the SCN1A, SCN2A or SCN3A genes, or a variant, equivalent, or mutation thereof which shows linkage disequilibrium therewith, to set-up a screening assay

for agents destined to modulate sodium channel function for the purpose of identifying agents having an application in epilepsy therapy.

10. A method for identifying, from a library of  
5 compounds, a compound with therapeutic effect on epilepsy or other neurological disorders comprising:

- a) providing a screening assay comprising a measurable biological activity of SCN1A, SCN2A or SCN3A protein or gene;
- 10 b) contacting said screening assay with a test compound; and
- c) detecting if said test compound modulates the biological activity of SCN1A, SCN2A or SCN3A protein or gene;

wherein a test compound which modulates said biological activity is a compound with said therapeutic effect.

15

11. The method of claim 10, wherein the test compound with said therapeutic effect is further modified by combinatorial or medicinal chemistry to provide further analogs of said test compound also having said therapeutic effect.

20

12. A compound having therapeutic effect on epilepsy or other neurological disorders, identified by a method comprising,

- a) providing a screening assay comprising a measurable biological activity of SCN1A, SCN2A or SCN3A protein or gene;
- 25 b) contacting said screening assay with a test compound; and
- c) detecting if said test compound modulates the biological activity of SCN1A, SCN2A or SCN3A protein or gene;

wherein a test compound which modulates said biological activity is a compound with said therapeutic effect.

13. The compound of claim 12, wherein the  
5 compound with said therapeutic effect is further modified by combinatorial or medicinal chemistry to provide analogs of said compound also having said therapeutic effect.